|
1
|
Ganesan P and Kulik LM: Hepatocellular
carcinoma: New developments. Clin Liver Dis. 27:85–102. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alawyia B and Constantina Constantinou:
Hepatocellular carcinoma: A narrative review on current knowledge
and future prospects. Curr Treat Options Oncol. 24:711–724. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu J, Shen M, Yue Z, Yang Z, Wang M, Li
C, Xin C, Wang Y, Mei Q and Wang Z: Triptolide inhibits
colon-rectal cancer cells proliferation by induction of G1 phase
arrest through upregulation of p21. Phytomedicine. 19:756–762.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oliveira A, Beyer G, Chugh R, Skube SJ,
Majumder K, Banerjee S, Sangwan V, Li L, Dawra R, Subramanian S, et
al: Triptolide abrogates growth of colon cancer and induces cell
cycle arrest by inhibiting transcriptional activation of E2F. Lab
Invest. 95:648–659. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei YS and Adachi I: Inhibitory effect of
triptolide on colony formation of breast and stomach cancer cell
lines. Zhongguo Yao Li Xue Bao. 12:406–410. 1991.PubMed/NCBI
|
|
6
|
Wang H, Ma D, Wang C, Zhao S and Liu C:
Triptolide inhibits invasion and tumorigenesis of hepatocellular
carcinoma MHCC-97H cells through NF-κB signaling. Med Sci Monit.
22:1827–1836. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li SG, Shi QW, Yuan LY, Qin LP, Wang Y,
Miao YQ, Chen Z, Ling CQ and Qin WX: C-Myc-dependent repression of
two oncogenic miRNA clusters contributes to triptolide-induced cell
death in hepatocellular carcinoma cells. J Exp Clin Cancer Res.
37:512018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu L, Qian J, Xue X, Pang M, Wang X, Li X,
Tian M, Lu C, Xiao C and Liu Y: Application of galactosylated
albumin for targeted delivery of triptolide to suppress
hepatocellular carcinoma progression through inhibiting de novo
lipogenesis. Biomed Pharmacother. 179:1174322024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alsaied OA, Sangwan V, Banerjee S, Krosch
TC, Chugh R, Saluja A, Vickers SM and Jensen EH: Sorafenib and
triptolide as combination therapy for hepatocellular carcinoma.
Surgery. 156:270–279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Yang G, Han L, Wang R, Gong C and
Yuan Y: Sorafenib and triptolide loaded cancer cell-platelet hybrid
membrane-camouflaged liquid crystalline lipid nanoparticles for the
treatment of hepatocellular carcinoma. J Nanobiotechnology.
19:3602021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xi C, Peng S, Wu Z, Zhou Q and Zhou J:
Toxicity of triptolide and the molecular mechanisms involved.
Biomed Pharmacother. 90:531–541. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Imai H and Nakagawa Y: Biological
significance of phospholipid hydroperoxide glutathione peroxidase
(PHGPx, GPx4) in mammalian cells. Free Radic Biol Med. 34:145–169.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nomura K, Imai H, Koumura T, Arai M and
Nakagawa Y: Mitochondrial phospholipid hydroperoxide glutathione
peroxidase suppresses apoptosis mediated by a mitochondrial death
pathway. J Biol Chem. 274:29294–29302. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nomura K, Imai H, Koumura T, Kobayashi T
and Nakagawa Y: Mitochondrial phospholipid hydroperoxide
glutathione peroxidase inhibits the release of cytochrome c from
mitochondria by suppressing the peroxidation of cardiolipin in
hypoglycaemia-induced apoptosis. Biochem J. 351:183–193. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang WS and Stockwell BR: Synthetic lethal
screening identifies compounds activating iron-dependent,
nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.
Chem Biol. 15:234–245. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu W, Yang Y, Wang J, Wu S and Chen Z:
Triptolide-mediated downregulation of FLIP(S) in hepatoma cells
occurs at the post-transcriptional level independently of
proteasome-mediated pathways. Med Oncol. 40:72022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao J, Jiang Z, Duan W, Huang J, Zhang L,
Hu L, He L, Li F, Xiao Y, Shu B and Liu C: Involvement of
mitochondrial pathway in triptolide-induced cytotoxicity in human
normal liver L-02 cells. Biol Pharm Bull. 31:592–597. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abou-Alfa GK, Schwartz L, Ricci S, Amadori
D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz
B, et al: Phase II study of sorafenib in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhai B and Sun XY: Mechanisms of
resistance to sorafenib and the corresponding strategies in
hepatocellular carcinoma. World J Hepatol. 5:345–352. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Xiao E, Yuan L and Li G: Triptolide
synergistically enhances antitumor activity of oxaliplatin in colon
carcinoma in vitro and in vivo. DNA Cell Biol. 33:418–425. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakazato T, Sagawa M and Kizaki M:
Triptolide induces apoptotic cell death of multiple myeloma cells
via transcriptional repression of Mcl-1. Int J Oncol. 44:1131–1138.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chugh R, Sangwan V, Patil SP, Dudeja V,
Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers
SM and Saluja AK: A preclinical evaluation of Minnelide as a
therapeutic agent against pancreatic cancer. Sci Transl Med.
4:156ra1392012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Liu R, Yang Y, Huang Y, Li X, Liu R
and Shen X: Triptolide-induced in vitro and in vivo cytotoxicity in
human breast cancer stem cells and primary breast cancer cells.
Oncol Rep. 31:2181–2186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Xu M, Peng Y, Naren Q, Xu Y, Wang
X, Yang G, Shi X and Li X: Triptolide enhances lipolysis of
adipocytes by enhancing ATGL transcription via upregulation of p53.
Phytother Res. 34:3298–3310. 2020. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang R, Guo F, Li Y, Liang Y, Li G, Fu P
and Ma L: Activation of AMPK by triptolide alleviates nonalcoholic
fatty liver disease by improving hepatic lipid metabolism,
inflammation and fibrosis. Phytomedicine. 92:1537392021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Y, Chen F, Wang S, Guo X, Shi P, Wang
W and Xu B: Low-dose triptolide in combination with idarubicin
induces apoptosis in AML leukemic stem-like KG1a cell line by
modulation of the intrinsic and extrinsic factors. Cell Death Dis.
4:e9482013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu X, Chen S, Huang K and Lin G:
Triptolide promotes ferroptosis by suppressing Nrf2 to overcome
leukemia cell resistance to doxorubicin. Mol Med Rep. 27:172023.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deng Y, Chu X, Li Q, Zhu G, Hu J, Sun J,
Zeng H, Huang J and Ge G: Xanthohumol ameliorates drug-induced
hepatic ferroptosis via activating Nrf2/xCT/GPX4 signaling pathway.
Phytomedicine. 126:1554582024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo L, Wang J, Zhao J, Yang B, Ma W and
Lin J: Dental pulp stem cells derived exosomes inhibit ferroptosis
via regulating the Nrf2-keap1/GPX4 signaling pathway to ameliorate
chronic kidney disease injury. Tissue Cell. 93:1026702025.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li S, He Y, Chen K, Sun J, Zhang L, He Y,
Yu H and Li Q: RSL3 drives ferroptosis through NF-κB pathway
activation and GPX4 depletion in glioblastoma. Oxid Med Cell
Longev. 2021:29150192021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Skouta R, Dixon SJ, Wang J, Dunn DE, Orman
M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A and
Stockwell BR: Ferrostatins inhibit oxidative lipid damage and cell
death in diverse disease models. J Am Chem Soc. 136:4551–4556.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fang X, Ardehali H, Min J and Wang F: The
molecular and metabolic landscape of iron and ferroptosis in
cardiovascular disease. Nat Rev Cardiol. 20:7–23. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shalev O, Repka T, Goldfarb A, Grinberg L,
Abrahamov A, Olivieri NF, Rachmilewitz EA and Hebbel RP:
Deferiprone (L1) chelates pathologic iron deposits from membranes
of intact thalassemic and sickle red blood cells both in vitro and
in vivo. Blood. 86:2008–2013. 1995. View Article : Google Scholar : PubMed/NCBI
|
